Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Sedation Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Sedation Overview | 8 | 1 |
| Sedation Therapeutics under Development by Companies | 9 | 1 |
| Sedation Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Sedation Products under Development by Companies | 13 | 1 |
| Sedation Companies Involved in Therapeutics Development | 14 | 8 |
| AstraZeneca Plc | 14 | 1 |
| Drawbridge Pharmaceuticals Pty Ltd | 15 | 1 |
| Jiangsu Nhwa Pharmaceutical Corporation Ltd. | 16 | 1 |
| NanoMedex Pharmaceuticals, Inc. | 17 | 1 |
| Paion AG | 18 | 1 |
| Primex Pharmaceuticals Oy | 19 | 1 |
| The Medicines Company | 20 | 1 |
| Therakind Limited | 21 | 1 |
| Sedation Therapeutics Assessment | 22 | 8 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 1 |
| Drug Profiles | 30 | 16 |
| ABP-700 Drug Profile | 30 | 2 |
| ADV-6209 Drug Profile | 32 | 1 |
| alphaxalone Drug Profile | 33 | 2 |
| clonidine hydrochloride Drug Profile | 35 | 1 |
| EL-001 Drug Profile | 36 | 1 |
| propofol Drug Profile | 37 | 1 |
| propofol microemulsion Drug Profile | 38 | 1 |
| remimazolam Drug Profile | 39 | 6 |
| Small Molecule to Agonize GABA-A for Sedation Drug Profile | 45 | 1 |
| Sedation Dormant Projects | 46 | 1 |
| Sedation Discontinued Products | 47 | 1 |
| Sedation Product Development Milestones | 48 | 10 |
| Featured News &Press Releases | 48 | 1 |
| Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy | 48 | 1 |
| Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy | 49 | 1 |
| Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment | 49 | 1 |
| Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy | 50 | 1 |
| Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan | 50 | 1 |
| Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia | 51 | 1 |
| Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy | 52 | 1 |
| May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward | 53 | 1 |
| Mar 31, 2015: PAION Announces Initiation of U.S. Phase 3 Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy | 53 | 1 |
| Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States | 54 | 1 |
| Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan | 54 | 1 |
| Oct 10, 2014: Paion Expects Ono S Remimazolm Decision On Filing In Japan In November 2014 | 54 | 1 |
| Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 | 55 | 1 |
| Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials | 56 | 1 |
| Jul 21, 2014: Drawbridge Pharmaceuticals extends Phaxan patent portfolio with divisional patents granted for other neuroactive steroids | 57 | 1 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |